19 April 2018
Prescription drug prices, particularly in the US, have been skyrocketing over the past decade at a significantly higher rate than inflation.
18 April 2018
Early top-line results from AnaptysBio’s Phase IIa trial of its IL-33-inhibiting biologic, ANB-020, in adult peanut allergy patients were released on March 26.
17 April 2018
A new epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treatment may be on the horizon for Molecular Partners.
12 April 2018
On 3 April, the US Trade Representative’s (USTR) office announced its intention to add a 25% tariff on around $50bn worth of Chinese imports across 1,300 categories of products.
3 April 2018
Pfizer’s flagship product Viagra is becoming available as an over-the-counter product for the treatment of erectile dysfunction for the first time.
28 March 2018
Bristol-Myers Squibb (BMS)’s anti-PD-1 Opdivo (nivolumab) is the first and only checkpoint inhibitor (CPI) approved for the treatment of advanced renal cell carcinoma (RCC) that progressed on prior anti-angiogenic therapy.
27 March 2018
Tilray has struck a deal with Sandoz, a division of the Novartis group, to be its supplier of medical cannabis products.
13 March 2018
Taiwanese company TaiMed Biologics has developed Trogarza, a new class of HIV therapeutic that represents the first innovator drug in this disease area in 10 years.
9 March 2018
There are more than 7,000 rare diseases identified, with 30 million of people affected in EU and US, however, only a fraction of them have approve treatment available.
5 March 2018
2017 represented a key year in the biosimilar landscape.